These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 32731765)
1. Hypomethylating agent-based post-transplant strategies to maximize the outcome of high-risk acute myeloid leukemia after allogeneic stem cell transplantation. Baek DW; Kim J; Cho HJ; Moon JH; Sohn SK Expert Rev Hematol; 2020 Sep; 13(9):959-969. PubMed ID: 32731765 [TBL] [Abstract][Full Text] [Related]
2. Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation. Tang Y; Zhou Z; Yan H; You Y Front Immunol; 2022; 13():810284. PubMed ID: 35185899 [TBL] [Abstract][Full Text] [Related]
3. Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: the role of hypomethylating agents. Martino M; Fedele R; Moscato T; Ronco F Curr Cancer Drug Targets; 2013 Jul; 13(6):661-9. PubMed ID: 23713435 [TBL] [Abstract][Full Text] [Related]
4. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents. Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031 [TBL] [Abstract][Full Text] [Related]
5. Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD. Yao S; Jianlin C; Zhuoqing Q; Yuhang L; Jiangwei H; Guoliang H; Hongmei N; Bin Z; Liangding H Front Immunol; 2021; 12():639217. PubMed ID: 33868266 [No Abstract] [Full Text] [Related]
6. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140 [TBL] [Abstract][Full Text] [Related]
7. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Schuler E; Wagner-Drouet EM; Ajib S; Bug G; Crysandt M; Dressler S; Hausmann A; Heidenreich D; Hirschbühl K; Hoepting M; Jost E; Kaivers J; Klein S; Koldehoff M; Kordelas L; Kriege O; Müller LP; Rautenberg C; Schaffrath J; Schmid C; Wolff D; Haas R; Bornhäuser M; Schroeder T; Kobbe G; Ann Hematol; 2021 Apr; 100(4):959-968. PubMed ID: 33191481 [TBL] [Abstract][Full Text] [Related]
8. Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Lee CJ; Shiraz P; Muffly L Leuk Lymphoma; 2017 Mar; 58(3):516-527. PubMed ID: 27685315 [TBL] [Abstract][Full Text] [Related]
9. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197 [TBL] [Abstract][Full Text] [Related]
10. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903 [TBL] [Abstract][Full Text] [Related]
11. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia. Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598 [TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133 [TBL] [Abstract][Full Text] [Related]
13. Clinical update on hypomethylating agents. Duchmann M; Itzykson R Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568 [TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial. Hyakuna N; Hashii Y; Ishida H; Umeda K; Takahashi Y; Nagasawa M; Yabe H; Nakazawa Y; Koh K; Goto H; Fujisaki H; Matsumoto K; Kakuda H; Yano M; Tawa A; Tomizawa D; Taga T; Adachi S; Kato K Pediatr Blood Cancer; 2019 Oct; 66(10):e27875. PubMed ID: 31309713 [TBL] [Abstract][Full Text] [Related]
15. Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia. Craddock C; Slade D; De Santo C; Wheat R; Ferguson P; Hodgkinson A; Brock K; Cavenagh J; Ingram W; Dennis M; Malladi R; Siddique S; Mussai F; Yap C J Clin Oncol; 2019 Mar; 37(7):580-588. PubMed ID: 30653424 [TBL] [Abstract][Full Text] [Related]
16. Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation. Xuan L; Wang Y; Huang F; Jiang E; Deng L; Wu B; Fan Z; Liang X; Xu N; Ye J; Lin R; Yin C; Zhang Y; Sun J; Han M; Huang X; Liu Q Cancer; 2018 May; 124(9):1954-1963. PubMed ID: 29509276 [TBL] [Abstract][Full Text] [Related]
17. Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Xuan L; Liu Q J Hematol Oncol; 2021 Jan; 14(1):4. PubMed ID: 33407700 [TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation. Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant. Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249 [TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study. Kawashima N; Ishikawa Y; Atsuta Y; Sawa M; Ozawa Y; Hayashi M; Kohno A; Tomita A; Maeda T; Sakaida E; Usuki K; Hagihara M; Kanamori H; Matsuoka H; Kobayashi M; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H; Cancer Sci; 2020 Jul; 111(7):2472-2481. PubMed ID: 32391628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]